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Abstract
Hepatic encephalopathy (HE) is an important cause of morbidity and mortality in patients with liver disease. The
pathogenesis of he is incompletely understood although ammonia and inflammatory cytokines have been implicated
as key mediators. To facilitate further mechanistic understanding of the pathogenesis of HE, a large number of
animal models have been developed which often involve the surgical creation of an anastomosis between the hepatic
portal vein and the caudal vena cava. One of the most common congenital abnormalities in dogs is a congenital
portosystemic shunt (cpss), which closely mimics these surgical experimental models of HE. Dogs with a cPSS often
have clinical signs which mimic clinical signs observed in humans with HE. Our hypothesis is that the pathogenesis
of HE in dogs with a cPSS is similar to humans with HE. The aim of the study was to measure a range of clinical,
haematological and biochemical parameters, which have been linked to the development of HE in humans, in dogs
with a cPSS and a known HE grade. One hundred and twenty dogs with a cPSS were included in the study and
multiple regression analysis of clinical, haematological and biochemical variables revealed that plasma ammonia
concentrations and systemic inflammatory response syndrome scores predicted the presence of HE. Our findings
further support the notion that the pathogenesis of canine and human HE share many similarities and indicate that
dogs with cPSS may be an informative spontaneous model of human HE. Further investigations on dogs with cPSS
may allow studies on HE to be undertaken without creating surgical models of HE thereby allowing the number of
large animals used in animal experimentation to be reduced.
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Introduction
Hepatic encephalopathy (HE) is a neuropsychiatric
syndrome which occurs in patients with significant liver
disorders [1]. The clinical signs of overt HE range from anxiety,
lethargy and apathy to gross disorientation and coma [2].
Hepatic encephalopathy has been estimated to occur in
approximately 30-45% of patients with cirrhosis and 10-50% of
patients with transjugular intrahepatic portosystemic shunt,
while minimal HE has been estimated to affect approximately
20-60% of patients with liver disease [3]. The estimated
prevalence of chronic liver disease and cirrhosis in the United
States is approximately 5.5 million cases and in 2003 there
were over 40 000 patients hospitalized for a primary diagnosis
of HE, resulting in total charges of approximately $932 million
[3]. In addition, trends over the past 10 years suggest that the
burden of HE is increasing, as indicated by increases in
hospital admissions and higher charges per stay [3].
Due to the significant morbidity and mortality associated with
HE, a large number of studies have been undertaken which
have examined the pathogenesis of this disorder. Whilst
ammonia has long been incriminated in the pathogenesis of HE
in humans [4], reports of an absolute correlation between blood
ammonia concentrations and severity of HE are not consistent
[5]; indeed, it is well recognised that some patients with severe
HE have normal ammonia concentrations [6]. Furthermore, two
controlled trials of ammonia administration to patients with
cirrhosis did not document development of HE [7,8].
This has prompted additional research, which has focussed
on understanding the role of other contributing factors which
may allow hyperammonemia, in the setting of advanced liver
disease, to cause HE in a high proportion of patients.
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Numerous studies have implicated other factors such as
manganese [9], hyponatremia [10] and inflammation in the
development of HE [5,11]. In terms of inflammation, a strong
positive correlation between circulating levels of TNFα and
severity of HE has been shown in patients with cirrhosis
[12,13]. In addition, induction of hyperammonemia by
administration of an amino acid solution to cirrhotic patients
without overt HE resulted in the development of HE only in the
presence of a systemic inflammatory response [14]. These
findings suggest that inflammation, particularly mediated by
TNFα, plays a crucial role in the neuropsychological effects of
hyperammonaemia in patients with liver disease. Thus, the
interaction between ammonia and inflammation/ infection
appears to be crucial in the development of HE although the
precise mechanism of how the interaction induces HE is
unclear [11,15,16].
Due to the large economic and social burden of HE and that
the pathophysiology of HE is incompletely understood, a
number of animal models of HE have been developed. These
typically involve inducing disease in healthy rodents or larger
animals such as dogs by invasive surgical or chemical
treatments. Portocaval anastomosis is the most widely used
rodent model of HE [17]. There are a number of problems with
this approach, including variations between studies in surgical
techniques and expertise, failure to induce the typical changes
in astrocytes observed in humans with HE, and inability to
consistently induce overt encephalopathy [17]. Bile duct ligation
is another model but animals rarely develop overt HE [17,18].
Hepatic encephalopathy can also be induced in rats by chronic
hyperammonemia induced by either ammonium-acetate
supplemented diet, parenteral administration of ammonium or
urease treatment [17].
Large animal models of HE have played an important role in
our understanding of HE as the syndrome was first described
in the 1890’s by Pavlov who observed that dogs developed a
behavioural syndrome following the formation of a surgical
shunt diverting blood away from the portal vein into the inferior
vena cava [11]. This approach remains one of the most widely
used models of HE and normally involves the creation of an
end-to-side portocaval shunt, which may be followed by
procedures such as ligation of the hepatic arteries or partial
hepatectomy [19,20]. This is typically done in pigs, but the
surgical creation of portocaval shunts in normal dogs is also a
well-established model of HE [21].
In contrast to experimentally induced HE in dogs,
spontaneous HE is well recognised in client-owned dogs with
naturally occurring liver diseases [22]. It can develop as a
complication of primary liver disease and secondary portal
hypertension or as consequence of congenital vascular
abnormalities termed portosystemic shunts (cPSS), which link
the portal vein directly with the systemic circulation [22].
Congenital portosystemic shunt is one of the most common
congenital abnormalities diagnosed in dogs [23]. Dogs with
cPSS usually have a single, extra-hepatic vessel which links
the portal vein and the caudal vena cava, although a range of
vascular abnormalities have been described [24]. In contrast to
healthy dogs with surgically created portocaval shunts, dogs
with a cPSS can present with signs that are similar to HE in
humans ranging from mild lethargy to ataxia, disorientation and
coma [22,25]. Dogs can be screened with good sensitivity and
specificity for cPSS by measurement of serum bile acids and
ammonia [26] and the abnormal vessel can be definitively
identified in almost all cases by either abdominal
ultrasonography, computed tomography or magnetic
resonance imaging [27-29].
We hypothesised that dogs with spontaneous cPSS would
be a good model for human HE. This hypothesis is supported
by our recent findings that dogs with cPSS have increased
whole blood concentrations of manganese and that dogs with a
cPSS have higher serum concentrations of C-reactive protein
compared to dogs with a cPSS which were asymptomatic,
observations which are similar to studies in human HE
[9,11,30,31]. We investigated this hypothesis by measuring a
range of clinical, haematological and biochemical variables,
including plasma ammonia and sodium concentrations and
systemic inflammatory response syndrome (SIRS) scores, in
120 dogs with a cPSS both with and without clinical signs of
HE. We found that both ammonia and SIRS scores predicted
the presence of HE in dogs with a cPSS. Our findings further
demonstrate the similarities between human and canine HE
and provide support for the concept that additional studies on
canine HE may not only provide mechanistic and therapeutic
insights into human HE but may also allow the scientific
community an opportunity to reduce the number of large
animals used in experimentation.
Results
Signalment
One hundred and twenty dogs were eligible for inclusion in
the study. Thirty-three were entire females, 18 neutered
females, 47 entire males and 22 neutered males. Their ages
ranged from 73 days to nearly 12 years with a median age of
333 days [highly skewed to right, mean was 649, 1st quartile
156, 3rd quartile 806]. The breeds of the dog included in the
study are shown in table 1. Ninety dogs had no clinical signs of
HE and the remaining 30 dogs had clinical signs consistent
with HE.
Uni-variable selection
The mean and standard deviation of the 12 variables
examined in this study are listed in table 2. Initially, 17
variables (12 measured plus 5 derived) were screened for their
ability to predict the presence of HE in which 11 were identified
as candidates with a univariable likelihood ratio test P-
value<=0.2. Of these total WBC concentration and the derived
indicator variable (WBC2) were highly correlated with the total
neutrophil concentration so were excluded. Details of
univariable selection are shown in table 3.
Multivariable analysis
Ammonia, lymphocyte, neutrophil and monocyte
concentrations were statistically significant predictors of the
presence of HE (table 4). When the SIRS score was included
as a linear predictor and its components excluded as individual
Inflammation Predicts Hepatic Encephalopathy
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candidate variables SIRS score and ammonia level were
significant predictors (table 5). The predictive power of both of
these models was at least acceptable with area under ROC
curves of 0.83 and 0.71 respectively.
The relationship between SIRS score and probability that a
dog had HE is shown in Figure 1 where SIRS score is plotted
against the logistic regression model coefficient (i.e. the log
odds ratio of HE at that score relative to odds at score zero)
with 95% confidence interval. The log-odds ratio increases
overall with increasing SIRS score although there was an initial
decrease between SIRS scores 0 and 1.
The further model using dichotomised SIRS score combined
with remaining candidate variables identified a SIRS score
greater than or equal to 3 as best dichotomous predictor of HE
Table 1. Breeds included in the study.
Breed count
Basset hound 1
Bichon Frise 5
Border Collie 2
Border Terrier 2
Cairn terrier 1
Cairn Terrier 2
Cavalier King Charles Spaniel 1
Chihuahua 1
Cocker Spaniel 5
Crossbreed 9
Flat Coat Retriever 1
Golden Retriever 3
Great Dane 1
Hovawart 1
Irish Setter 2
Irish Water Spaniel 1
Jack Russel 5
Jack Russell Terrier 1
Labrador 7
Lhasa Apso 2
Maltese Terrier 1
Minature Schnauzer 1
Miniature Dachshund 1
Miniature Poodle 2
Miniature Schnauzer 7
Norfolk Terrier 5
Papillon 1
Pug 3
Rhodesian Ridgeback 1
Scottish Terrier 1
Shetland Sheepdog 1
Shih Tzu 9
Springer Spaniel 1
Staffordshire Bull Terrier 1
Tibetan Terrier 1
Weimaraner 1
West Highland White Terrier 17
Yorkshire Terrier 13
doi: 10.1371/journal.pone.0082303.t001
(see table 6). Ammonia concentration was also a significant
predictor in this model with a coefficient and odds ratio similar
to the other models and an area under the ROC curve of 0.73.
Table 2. Mean and standard deviation (brackets) of clinical,
haematological and biochemical variables in dogs without
and with HE.
Variable No HE HE
Ammonia μmol/l 152.6 (101.6) 225.8 (132.0)
PCV % 41.4 (6.7) 39.8 (6.7)
Na mmol/l 148.3 (3.8) 149.7 (3.9)
Lymphocytes x109/l 3.2 (1.6) 2.7 (1.4)
Neutrophils x109/l 9.2 (3.4) 12.5 (6.9)
Monocytes x109/l 0.9 (0.6) 1.6 (1.4)
WBC x109/l 14.1 (4.5) 17.7 (8.2)
RBC x1012/l 6.7 (1.1) 6.4 (1.1)
Temperature °C 38.3 (0.5) 38.5 (0.6)
Heart rate /min 113.4 (30.4) 120.2 (35.5)
Respiratory rate /min 29.2 (12.5) 36.1 (18.0)
K mmol/l 4.6 (0.4) 4.5 (0.4)
doi: 10.1371/journal.pone.0082303.t002
Table 3. Univariable analysis testing individual variable’s
ability to predict presence of HE (‡ variables are binary
variables based on the SIRS score components – see
methodology).
Variable
Likelihood ratio test
P-Value
Candidate for multivariable
model development (*)
Ammonia μmol/l 0.0029 *
SIRS 0.0114 *
PCV % 0.2543  
Na mmol/l 0.0964 *
Lymphocytes x109/l 0.1006 *
Neutrophils x109/l 0.0012 *
Monocytes x109/l 0.0008 *
WBC x109/l 0.0044 (Excluded as highly correlatedwith neutrophil count)
RBC x1012/l 0.1139 *
Temperature °C 0.0563 *
Heart rate /min 0.3180  
Respiratory rate /min 0.0271 *
K mmol/l 0.3703  
RR2‡ 0.2095  
HR2‡ 0.2633  
WBC2‡ 0.0651 (Excluded as highly correlatedwith neutrophil count)
Temp2‡ 0.2633  
doi: 10.1371/journal.pone.0082303.t003
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Follow up on encephalopathic dogs post treatment
To further probe the role of ammonia and SIRS in the
development of HE, we investigated how these variables
changed in the dogs with hepatic encephalopathy following
Table 4. Multivariable model predicting presence of HE
developed from all candidate variables excluding SIRS
score.
Variable Estimate Odds Ratio Std. Error P-Value
Ammonia 0.0063 1.0063 0.00255 0.0136
Na 0.1105 1.1168 0.07556 0.1436
Lymphocytes -0.6892 0.5020 0.22193 0.0019
Neutrophils 0.1551 1.1678 0.07027 0.0273
Monocytes 0.7958 2.2161 0.39006 0.0413
RBC -0.4947 0.6097 0.25707 0.0543
doi: 10.1371/journal.pone.0082303.t004
Table 5. Multivariable model predicting presence of HE
developed from SIRS score and independent candidate
variables.
Variable Estimate Odds Ratio Std. Error P-Value
Ammonia 0.0050 1.00497 0.0019 0.00979
SIRS score 0.4782 1.61324 0.2314 0.03876
doi: 10.1371/journal.pone.0082303.t005
successful treatment of HE. From the cohort of 30 dogs with
HE, 25 were asymptomatic after surgical attenuation of the
anomalous vessel at a mean time follow up time of 3.5 months
after surgery. In the 25 dogs whose HE resolved following
surgery, the plasma ammonia concentration significantly
dropped from a pre-treatment median concentration of
251.1µmol/l to a post-treatment median of 79.5µmol/l (p=0.007,
n=18). There was no significant difference in SIRS before and
after treatment (pre mean 2.12 median 2, post mean 1.57
median 2; p=0.13, n=14).
Discussion
The central finding of this study is that both ammonia and
inflammation predicts the presence of HE. Whilst ammonia has
long been established to be increased in dogs with a cPSS
[26], its role in the development of HE has received limited
Table 6. Multivariable model predicting presence of HE
developed from dichotomised SIRS score and independent
selected variables.
Variable Estimate Odds Ratio Std. Error P-Value
Ammonia 0.0043 1.0043 0.0019 0.0260
Na 0.107 1.1131 0.0649 0.0988
RBC -0.368 6.9201 0.2262 0.1036
SIRS >= 3 1.097 2.9953 0.5182 0.0343
doi: 10.1371/journal.pone.0082303.t006
Figure 1.  SIRS score plotted against log (odds ratio) of HE relative to reference value of SIRS 0.  
doi: 10.1371/journal.pone.0082303.g001
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attention, particularly in the context of a cPSS [32]. This study
has clearly shown that in dogs, plasma ammonia is predictive
for the presence of HE, observations which are similar to
studies in humans with HE [6,13]. Ammonia is widely
considered to initiate HE through altered astrocytes function as
these are the main cells in the brain that can metabolise
ammonia. The conversion of glutamate and ammonia to
glutamine results in osmotic stress leading to astrocyte
swelling, cerebral oedema and intracranial hypertension [33].
However, it is important to acknowledge that several dogs
with HE had a normal plasma ammonia concentration. This
finding highlights that hyperammonemia is not a universal
finding in dogs with a cPSS and HE and suggests that other
factors are likely to be important in the initiation of HE in these
dogs. Again, this finding is similar to studies in humans which
have found that although ammonia is frequently raised in
patients with HE, there is an imperfect correlation between
ammonia and severity of HE signs [5]. There is a substantial
overlap between ammonia concentrations and various grades
of HE with some patients with HE having normal ammonia
concentrations [6,13]. This result is also consistent with the
observation that dogs with urea cycle enzyme deficiency have
increased plasma ammonia concentrations but do not typically
developing clinical signs of HE [34]. It is also supported by the
finding that humans, when administered ammonium chloride,
do not develop classical signs of HE [35].
The additional main finding of this study is that a high SIRS
score was predictive of HE in dogs with a cPSS. This finding is
consistent with studies in humans with liver disease and HE
[36-39]. The mechanism by which a SIRS may influence the
development of HE is unclear although the presence of a SIRS
has been shown to exacerbate the neuropsychological effects
of induced hyperammonemia in humans [14]. Our study did not
find any evidence of an additive effect of ammonia and
inflammation, rather we found that HE was associated with the
presence of inflammation and hyperammonemia as
independent, non-interacting events.
The finding that ammonia decreases in dogs with HE whose
encephalopathic signs resolved following treatment, further
supports the notion that ammonia plays a key role in the
development of HE. The observation that the mean SIRS score
decreased post successful treatment of HE is compatible with
the concept that inflammation is important in development of
HE. The lack of statistical significance associated with the
decrease of SIRS score following treatment may be a
consequence of statistical power as the number of paired
samples was lower than in the ammonia analysis. Also, the 4
point, categorical nature of the SIRS score means that it lacks
sensitivity to detect of changes in inflammation. For example,
the temperature, heart rate, respiratory rate and white cell
count may have all decreased following treatment but if they
did not cross the cut offs used, the SIRS score would not
register these changes.
The finding that plasma sodium concentrations did not
predict the presence of HE is noteworthy. The presence of
hyponatremia is well recognised in humans with liver diseases
[10]. In patients with cirrhosis the presence of hyponatremia
has been associated with increased risk of developing
electroencephalographic abnormalities and HE [40-42]. In
addition, the presence of hyponatremia identifies patients with
HE that are more resistant to treatment with lactulose [43]. The
mechanism by which hyponatriema exacerbates HE is unclear
although astrocyte swelling due to reduced osmolality of the
extracellular fluid is widely postulated to be important [44,45].
The lack of association between sodium concentrations and
HE in dogs with a cPSS may reflect the fact that hyponatremia
is only rarely diagnosed in dogs with a cPSS. Hyponatremia
may be a rare finding in dogs with a cPSS since portal
hypertension and ascites does not occur in dogs unless there
is a concurrent primary hepatopathy.
The cross sectional design of this study does not allow us to
establish that ammonia and inflammation initiate HE in dogs
with a cPSS. Longitudinal and provocative testing would be
required to further investigate whether ammonia and
inflammation play a causative role in spontaneous HE in dogs
with a cPSS. In addition, we did not evaluate all other factors
which have been linked to HE in dogs such as manganese
[30], gastrointestinal derived endogenous benzodiazepines
[46], hypercortisolism [47] and altered tryptophan metabolism
[48]. However, our work clearly demonstrates that both
ammonia and inflammation predicts the presence of HE in
dogs with a cPSS and provides further evidence that dogs with
a cPSS are a good spontaneous model of human HE, notably
type B HE [1,49]. Further studies into the pathogenesis of HE
in dogs with a cPSS may offer additional insights into the
biology of HE in humans and could potentially reduce the
numbers of large animals used in animal experimentation.
Methods
Consecutive cases of dogs with a cPSS diagnosed at the
Royal Veterinary College, London were considered eligible for
inclusion in the study. The diagnostic criteria for a cPSS were
the identification of a portosystemic shunt on intra-operative
mesenteric portovenography and by visual identification of
shunting vessel during an exploratory celiotomy. The presence
or absence of HE at the time of blood sampling and clinical
examination was ascertained by reviewing the case notes. The
dog was considered to have HE if it had clinical signs of
lethargy, inappropriate behaviour, disorientation, circling, head
pressing or seizures [50]. If the dog had no clinical signs of
neurological impairment or dysfunction it was considered to not
have HE. Details of each dog’s heart rate, respiratory rate,
temperature, haematology profile and plasma ammonia,
sodium and potassium concentrations were recorded.
Ammonia was measured using either a spectrophotometer
Stasar III Spectrophotometer (Gilford Instrument Laboratories
Incorporated, Ohio, USA) or a Jenway 6310
Spectrophotometer (Bibby Scientific Limited, Staffordshire,
UK). Haematology was performed using an Abbott Cell-Dyn
3500 (Abbott Diagnostics Limited, Berkshire, UK). Sodium was
measured using either a Technicon OPERA Chemistry
Analyzer (Bayer Diagnostics, Hampshire, UK) or an IL ILab 600
Chemistry Analyzer (Instrumentation Laboratory, Cheshire,
UK).
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Records were available for 120 dogs with complete
observation of these 12 variables. A SIRS score was calculated
for each dog using the methodology previously described
[51,52]. The SIRS score records how many of the following
criteria were met for each dog: respiratory rate greater than 20
min-1 [RR2]; heart rate greater than 120 min-1 [HR2]; total
WBC less than 6 or greater than 16 x109 L-1 [WBC2] and rectal
temperature less than 38.1 or greater than 39.2 degrees
Celsius [Temp2]. SIRS scores could hence take a value from 0
to 4. The four, binary, variables recording each of criteria
individually (RR2, HR2, WBC2 and Temp2) were also added
for each dog.
Prior to development of the multivariable models, the 17 (12
measured plus 5 derived) variables were screened individually
to assess their association with the presence of HE. Variables
with a likelihood ratio test P-value<=0.2 on logistic regression
analysis were selected as candidates for inclusion in the
multivariable models. Multi-collinearity (strong correlation of
variables that may produce spurious statistical results) was
assessed by scatter-plots and Pearson’s product moment
correlation.
Two multivariable logistic regression models predicting the
presence of HE were then developed; one using all the
candidate variables from univariable screening excluding the
SIRS score; the other using the ordinal (0-4) SIRS score and
those candidate variables that were not components of the
SIRS score (RBC, Sodium and Ammonia). Final multivariable
models were built using stepwise selection based on Akaike
Information Criteria (AIC – a measure of model fit with a
penalty for number of parameters used). To reduce the effect
of confounding, variables were retained in the multivariable
model, even if they were individually statistically non-significant
(using a critical p-value of 0.05), if their exclusion altered the
coefficients of statistically significant predictors by more than
10%. The validity of including continuously measured variables
and the ordinal variable, SIRS score, as linear predictors on the
log-odds scale was checked by examination of density/
frequency plots of the variables for the HE and non-HE
outcomes and by categorisation of the continuous predictors
and estimation of coefficients for each category to detect
grossly non-linear relationships. Model goodness of fit was
assessed using the Hosmer-Lemeshow test. The predictive
ability of the models was assessed by estimation of area under
the receiver operating characteristic curve. A further model was
developed to identify a single optimal cut-off value of SIRS
score as a dichotomous predictor of HE using AIC as the
model selection criteria. Ammonia concentrations and SIRS
were compared before and after treatment by a Wilcoxon
matched-pairs test. Data management and statistical analysis
used the R statistical system (R Development Core Team
(2012)). The study was approved by the Royal Veterinary
College Ethics Committee. The owners of the dogs gave
permission for their animals to be used in this study.
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